% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Frost:278915,
      author       = {Frost, Bess and Rowe, James B and Akinyemi, Rufus O and
                      Abisambra, Jose F and Ashton, Nicholas J and Brendel,
                      Matthias and Buée, Luc and Butler, David and Carrillo,
                      Maria C and Chung, Peter and Clelland, Claire D and DeVos,
                      Sarah L and Diaz, Kristophe and Edelmayer, Rebecca M and
                      Elahi, Fanny M and Ellajosyula, Ratnavalli and Ewen, Colin
                      and Fontana, Igor Camargo and Galas, Marie-Christine and
                      Hansson, Oskar and Höglinger, Günter and Horie, Kanta and
                      Ibanez, Agustín and Jacobs, Linde and Maina, Mahmoud B and
                      Malpetti, Maura and McDade, Eric and McEwan, Will and
                      Montoliu-Gaya, Laia and Mummery, Catherine J and Orr,
                      Miranda E and Rohrer, Jonathan D and Rommel, Amy and Sastre,
                      Carlos and Spires-Jones, Tara L and Tee, Boon Lead and
                      Viney, Tim J and Walker, Jamie M and Wegmann, Susanne and
                      Wildsmith, Kristin and Yadav, Ravi and Mahinrad, Simin and
                      Sexton, Claire},
      title        = {{I}nsights into pathophysiology, biomarkers, and
                      therapeutics in tauopathies: {P}roceedings of the {T}au2024
                      {G}lobal {C}onference.},
      journal      = {Alzheimer's and dementia},
      volume       = {21},
      number       = {5},
      issn         = {1552-5260},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DZNE-2025-00641},
      pages        = {e70078},
      year         = {2025},
      abstract     = {Recent years have seen major advances in tau-associated
                      brain disorders through interdisciplinary research spanning
                      molecular biology, neuroimaging, clinical trials, and
                      therapeutic development. The Tau2024 Global Conference,
                      hosted by the Alzheimer's Association, CurePSP, and
                      Rainwater Charitable Foundation, showcased these efforts by
                      bringing together researchers and experts worldwide to
                      discuss the latest advancements in tau research. The
                      conference aimed to attract talent and funding to study
                      tauopathies, particularly among early-career researchers,
                      and to foster interdisciplinary alignment and collaboration
                      around challenges in tau research. In this manuscript, we
                      summarize proceedings of the Tau2024 Global Conference,
                      covering a wide range of topics, including lived experiences
                      of individuals with genetic forms of tauopathies, global
                      perspectives on tauopathies, and molecular mechanisms, brain
                      microenvironments, biomarker developments, clinical trials,
                      and therapeutic approaches to tauopathies. Through
                      international, collaborative efforts, innovative research,
                      and a commitment to inclusivity, researchers worldwide have
                      demonstrated transformative breakthroughs toward diagnosing,
                      treating, and, ultimately, preventing tau-related diseases.
                      HIGHLIGHTS: The Tau2024 Global Conference presented updates
                      and advances in tau research. Blood-based biomarkers offer
                      specificity and longitudinal monitoring capabilities. There
                      are a range of targetable mechanisms in the cascade of
                      pathogenesis. International collaboration is vital to
                      address disparities in tauopathies.},
      subtyp        = {Review Article},
      keywords     = {Humans / Tauopathies: therapy / Tauopathies:
                      physiopathology / Tauopathies: diagnosis / Tauopathies:
                      genetics / Biomarkers: metabolism / Congresses as Topic /
                      tau Proteins: metabolism / Brain: pathology / Brain:
                      metabolism / Alzheimer's disease (Other) / neurodegenerative
                      disease (Other) / tau disorder (Other) / tau protein (Other)
                      / tauopathies (Other) / Biomarkers (NLM Chemicals) / tau
                      Proteins (NLM Chemicals)},
      cin          = {AG Haass / Clinical Research (Munich) / AG Wegmann},
      ddc          = {610},
      cid          = {I:(DE-2719)1110007 / I:(DE-2719)1111015 /
                      I:(DE-2719)1810006},
      pnm          = {352 - Disease Mechanisms (POF4-352) / 353 - Clinical and
                      Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-352 / G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40437880},
      doi          = {10.1002/alz.70078},
      url          = {https://pub.dzne.de/record/278915},
}